Ritholtz Wealth Management Trims Stake in Haleon PLC Sponsored ADR (NYSE:HLN)

Ritholtz Wealth Management reduced its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 22.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,014 shares of the company’s stock after selling 13,200 shares during the period. Ritholtz Wealth Management’s holdings in Haleon were worth $473,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in HLN. FMR LLC grew its position in Haleon by 3.7% in the fourth quarter. FMR LLC now owns 108,827,814 shares of the company’s stock worth $1,038,217,000 after acquiring an additional 3,909,545 shares in the last quarter. Wellington Management Group LLP grew its position in Haleon by 67.5% in the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after acquiring an additional 6,175,835 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Haleon by 0.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,630,307 shares of the company’s stock worth $72,793,000 after acquiring an additional 58,444 shares in the last quarter. JPMorgan Chase & Co. grew its position in Haleon by 18.3% in the fourth quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company’s stock worth $57,382,000 after acquiring an additional 930,701 shares in the last quarter. Finally, Northern Trust Corp grew its position in Haleon by 27.7% in the fourth quarter. Northern Trust Corp now owns 5,412,542 shares of the company’s stock worth $51,636,000 after acquiring an additional 1,172,931 shares in the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. HSBC reiterated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. BNP Paribas raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, May 27th. Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. BNP Paribas Exane raised shares of Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 price target for the company in a research note on Tuesday, May 27th. Finally, Barclays reissued an “overweight” rating on shares of Haleon in a research note on Tuesday, May 6th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Stock Performance

Shares of NYSE:HLN opened at $10.45 on Friday. The company has a market cap of $46.99 billion, a price-to-earnings ratio of 26.78, a price-to-earnings-growth ratio of 2.98 and a beta of 0.31. The company has a 50-day moving average price of $10.68 and a 200-day moving average price of $10.10. The company has a current ratio of 0.98, a quick ratio of 0.78 and a debt-to-equity ratio of 0.53. Haleon PLC Sponsored ADR has a 12 month low of $8.25 and a 12 month high of $11.42.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.